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ABSTRACT: Cancer cells possess fundamentally altered
metabolism that supports their pathogenic features, which
includes a heightened reliance on aerobic glycolysis to provide
precursors for synthesis of biomass. We show here that inositol
polyphosphate phosphatase 1 (INPP1) is highly expressed in
aggressive human cancer cells and primary high-grade human
tumors. Inactivation of INPP1 leads to a reduction in
glycolytic intermediates that feed into the synthesis of the
oncogenic signaling lipid lysophosphatidic acid (LPA), which in turn impairs LPA signaling and further attenuates glycolytic
metabolism in a feed-forward mechanism to impair cancer cell motility, invasiveness, and tumorigenicity. Taken together these
ﬁndings reveal a novel mode of glycolytic control in cancer cells that can serve to promote key oncogenic lipid signaling pathways
that drive cancer pathogenicity.
Cancer cells undergo a fundamental reprogramming of keybiochemical pathways that fuel cell proliferation. These
alterations include an addiction to aerobic glycolysis (known as
the Warburg eﬀect), heightened lipogenesis, as well as an
increase in glutamine-dependent anaplerosis.1,2 However, the
metabolic reprogramming that drives the aggressive features of
cancer, such as motility, invasiveness, and tumor-initiating
capacity, is not well-understood. Since most cancer deaths are
related to aggressive features of cancer, understanding the
metabolic pathways that contribute to these pathogenic features
of cancer is critical for both diagnosis and treatment.
We previously identiﬁed a gene expression signature of
commonly dysregulated metabolic enzymes that were height-
ened across a panel of highly aggressive human cancer cells,
leading us to hypothesize that there was a metabolic program
that supports cancer malignancy.3 Consistent with this premise,
two of these enzymes, monoacylglycerol lipase (MAGL) and
KIAA1363, have been previously shown to be important in
maintaining aggressive and tumorigenic features of cancer
through modulating protumorigenic fatty acid or ether lipid
derived signaling molecules, respectively.3−6 Here, we show
that inositol polyphosphate phosphatase 1 (INPP1), another
enzyme found in this gene expression signature, is highly
upregulated across aggressive human cancer cells and high-
grade primary human tumors. The established biochemical role
of INPP1 is to dephosphorylate free polyphosphorylated
inositols.7 While INPP1 has been previously shown to be
upregulated in human colorectal cancers, the role of this
enzyme in cancer has remained obscure.8 In this study, we
show that INPP1 drives cancer pathogenicity through
controlling glycolytic pathways that feed into the generation
of oncogenic signaling lipids. We ﬁnd that inactivation of
INPP1 impairs aggressive and tumorigenic features of cancer
through impairing protumorigenic lipid signals derived from
glycolytic metabolism.
■ RESULTS AND DISCUSSION
INPP1 Activity Is Upregulated in Aggressive Cancer
Cells and Primary Human Tumors. Gene expression
analysis comparing a panel of aggressive breast, prostate,
ovarian, and melanoma cancer cell lines with their less
aggressive counterparts4 previously revealed a commonly
dysregulated signature of metabolic enzymes. These aggressive
cancer cells do not show heightened proliferative capacity
(Supplementary Figure S1A) but exhibit high migratory,
invasive, and tumor-forming capacity compared to the less
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aggressive cancer cells.3 Among this signature, hydroxypruvate
isomerase (HYI) and INPP1 were the only enzymes that act
upon small-molecule substrates, exhibit a greater than 2-fold
higher expression across aggressive cancer cells, and have also
not been previously studied in cancer. INPP1 inactivation with
RNA interference, but not HYI knockdown, led to migratory
defects in cancer cells (Supplementary Figure S1B). Thus, we
decided to focus our subsequent eﬀorts on investigating the
role of INPP1 in cancer. We ﬁnd that INPP1 expression,
protein levels, and enzyme activity are signiﬁcantly elevated
across aggressive melanoma, prostate, ovarian, and breast
cancer cells compared to their less aggressive counterparts
(Figure 1A−C). INPP1 activity or expression is also
signiﬁcantly elevated in high-grade primary ovarian and
melanoma tumors compared to low-grade ovarian tumors and
normal skin tissue, respectively (Figure 1D). INPP1 was not
diﬀerentially expressed in primary human breast tumors (Figure
1D). INPP1 protein expression is also upregulated upon
overexpression of several commonly mutated or ampliﬁed
human oncogenes (PI3KCA, activated MAP kinase
Figure 1. INPP1 is highly expressed in aggressive cancer cells and primary tumors. (A−C) INPP1 gene (A) and protein (B) expression and INPP1
activity (C) across aggressive ovarian, melanoma, breast, and prostate cancer cells (SKOV3, C8161, 231MFP, and PC3) compared to their less
aggressive counterparts (OVCAR3, MUM2C, MCF7, and LNCaP) as measured by quantitative PCR (qPCR) (A), Western blotting (B), and
inositol-1,4-bisphosphate phosphatase activity measuring inositol phosphate product formation by LC−MS (C). (D) INPP1 enzyme activity (for
ovarian tumors) and mRNA expression (for melanoma and breast tumors) in high-grade compared to low-grade primary human ovarian tumors or
melanoma or breast tumors compared to normal tissue. *p < 0.05. Data are presented as mean ± SEM; n = 3−5/group for panels A−C and n = 3−
39 for panel D.
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(MEKDD1), HRAS, NeuNT, and BRAF) in MCF10A
nontransformed mammary epithelial cells (Supplementary
Figure S1C). These oncogenes have been previously associated
with both transformation of cancer cells and acquisition of
cancer malignancy.9−11 Taken together, our results indicate that
INPP1 expression is heightened in aggressive cancer cells and
primary human ovarian and melanoma tumors and upon
induction of MCF10A cells by several human oncogenes.
Disruption of INPP1 Impairs Cancer Pathogenicity.
We next sought to ascertain the pathophysiological role of
INPP1 in cancer. Since INPP1 is upregulated in high-grade
human ovarian and melanoma tumors, but not in primary
Figure 2. INPP1 inactivation leads to impairments in cancer pathogenicity. (A) INPP1 was knocked down using both a short-hairpin RNA (shRNA)
oligonucleotide (shINPP1) as well an small-interfering RNA (siRNA) oligonucleotide (siINPP1), resulting in >70% reduction in both INPP1
expression and activity in C8161 and SKOV3 cells compared to their respective sh and siControl cells. (B,C) shINPP1 and siINPP1 cells show
decreased migration (B) and invasion (C) compared to shControl and siControl cells in both SKOV3 and C8161 cells. Migration and invasion
assays were performed by transferring cancer cells to serum-free media for 4 h prior to seeding 50,000 cells into inserts with 8 μm pore size
containing membranes coated with collagen (10 μg/mL) or BioCoat Matrigel, respectively. C8161 and SKOV3 migration times were 5 and 8 h,
respectively. Migrated or invaded cells refer to average numbers ± SEM per four ﬁelds counted at 400 X magniﬁcation. (D) shINPP1 cells show
impaired tumor growth in SCID mice compared to shControl cells. A total of 2 ×106 C8161 or SKOV3 cells/100 μL were injected subcutaneously
into the ﬂank, and tumor growth was measured using calipers. Signiﬁcance is presented as *p < 0.05 compared to shControl or siControl. Data are
presented as mean ± SEM; n = 3 or 4/group for panels A−C and n = 5 or 6/group for panel D.
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human breast tumors, we focused our attention on the role of
INPP1 in ovarian and melanoma cancer cells. We knocked
down the expression of INPP1 in both aggressive and less
aggressive SKOV3 and OVCAR3 ovarian and C8161 and
MUM2C melanoma cancer cells with short-hairpin (shINPP1)
or small-interfering (siINPP1) RNA oligonucleotides, respec-
tively, resulting in a 70−80% reduction in INPP1 expression,
protein level, and activity (Figure 2A; Supplementary Figure
S1D,E). INPP1 inactivation signiﬁcantly impairs cancer cell
migration and invasiveness in both the aggressive and less
aggressive ovarian and melanoma cancer cells, without eﬀects
on cellular proliferation or serum-free cell survival (Figure
2B,C; Supplementary Figure S1E−G). We conﬁrmed the
speciﬁcity of the INPP1 knockdown eﬀects by recapitulating
our antimigratory eﬀects with two independent siRNA
oligonucleotides for INPP1 as well as partially to fully rescuing
the migratory defect with reinforced expression of INPP1 in
siINPP1 SKOV3 cells (Supplementary Figure S1E,H). Since
INPP1 was discovered as upregulated across aggressive cancer
cells that possess heightened migratory, invasive, and
tumorigenic properties but are not more proliferative, we
interpret our results to indicate that INPP1 may be more
important in maintaining aggressive or tumor-initiating features
of cancer. Consistent with this premise, INPP1 inactivation in
SKOV3 and C8161 cells slows tumor xenograft growth in
immune-deﬁcient mice (Figure 2D). These data indicate that
INPP1 is necessary to maintain cancer cell motility,
invasiveness, and tumorigenicity in ovarian and melanoma
cancer cells both in situ and in vivo.
We overexpressed INPP1 in the ovarian cancer cells
OVCAR3 and SKOV3 and melanoma cancer cells MUM2C
but did not observe increases in cell migration, invasiveness,
proliferation, or survival, indicating that INPP1 alone may not
be suﬃcient to confer malignant properties to cancer cells (data
not shown).
INPP1 Controls the Levels of Glycolytic Intermediates
and Oncogenic Signaling Lipids.While INPP1 is known for
its role in inositol phosphate metabolism, we were perplexed by
how this role could aﬀect cancer pathogenicity. We thus
performed a large-scale metabolomic proﬁling study to identify
metabolites that may be altered upon inactivation or over-
expression of INPP1 in cancer cells, using single reaction
Figure 3. Metabolomic proﬁling links INPP1 to glycolysis and lipid metabolism. (A) Metabolomic analyses of cancer cell steady-state metabolomes
with impaired INPP1 activity compared to control cells. The volcano plot shows all ions that were detected by targeted or untargeted metabolomic
proﬁling of shControl and shINPP1 SKOV3 cells. Gray points show the ions and metabolites that were not signiﬁcantly altered between shControl
and shINPP1 cells. The red and blue points to the right of the dotted black line are metabolites that were signiﬁcantly (p < 0.05) and commonly
elevated or lowered, respectively, across C8161 and SKOV3 sh and siINPP1 compared to their respective sh and siControl cells. C16:0, C18:0,
C18:1 refer to acyl chain length:unsaturation on LPA. C16:0e LPAe refers to the ether lipid counterpart of LPA (LPA-ether). All targeted data are in
Supplementary Table S1. (B,C) Levels of metabolites that were altered upon INPP1 knockdown in SKOV3 (B) and C8161 (C) cells, quantiﬁed by
SRM. Data are presented as means ± SEM of n = 4 or 5/group with signiﬁcance expressed as *p < 0.05 for INPP1 knockdown compared to control.
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monitoring (SRM)-based targeted methods as well as
untargeted liquid chromatography−mass spectrometry (LC−
MS)-based metabolomic platforms. We quantitatively measured
>130 metabolites using SRM-based targeted methods and
>12,000 ions with our untargeted methods coupled to
bioinformatic analysis using XCMSOnline12 (Figure 3A−C)
(targeted data shown in Supplementary Table S1). Upon
ﬁltering for metabolites that were commonly and signiﬁcantly
altered in both sh and siINPP1 cells in both SKOV3 and C8161
lines, we ﬁnd that INPP1 inactivation leads to reductions in the
levels of the product of INPP1, inositol phosphate (IP), as well
as reductions in glycolytic intermediates glucose-6-phosphate
Figure 4. INPP1 modulates glycolytic and glucose-derived LPA metabolism. (A) Media glucose and lactate levels at 0, 8, 16, and 24 h in siControl
and siINPP1 cells, measured by glucose assay kit and SRM-based LC−MS/MS, respectively. (B) Steady-state isotopic [13C] incorporation into
glycolytic intermediates from treatment of siControl and siINPP1 SKOV3 cells with either 10 mM concentration of nonisotopic glucose or 10 mM
concentration of isotopic [U-13C]glucose for 24 h in otherwise glucose-free RPMI1640 media. Conﬁrmation that we are measuring isotopic
glycolytic intermediates at steady state is provided in Supplementary Figure S4. Full isotopomer distribution of metabolites is shown in
Supplementary Figure S5. (C) Relative gene expression by qPCR of glucose transporters and glycolytic enzymes in SKOV3 and C8161 cells of
siControl (black) compared with siINPP1 (blue) cells. (D) Phenotypic and metabolic eﬀects of 2-deoxyglucose (2-DG) in SKOV3 cells. Treatment
of SKOV3 cells with 2-DG (in water, 5 mM, 24 h) impairs SKOV3 cell migration (right panel) and lowers post-PGI glycolytic intermediates and
LPA levels (left panel). (E) GLUT4 overexpression partially rescues migratory deﬁcits conferred by INPP1 knockdown in SKOV3 cells. qPCR of
GLUT4 expression is shown in the left panel, and migration data are shown in the right panel. Data are presented as means ± SEM of n = 3−5/
group with signiﬁcance expressed as *p < 0.05 compared to siControl or control cells and #p < 0.05 comparing siINPP1+GLUT4 to siINPP1 groups.
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(glucose-6-P) and glyceraldehyde-3-phosphate/dihydroxyace-
tone phosphate (G3P/DHAP), metabolites in glycerophos-
pholipid synthesis glycerol-3-phosphate (glycerol-3P) and
lysophosphatidic acid (LPA) levels, and the ether lipid LPA-
ether (LPAe) (Figure 3A−C; Supplementary Table S1). We
also observe increases in the levels of the amino acid asparagine.
Additional changes in other glycolytic intermediates were also
observed in siINPP1 SKOV3 and C8161 cells, including as
Figure 5. LPA modulates the migratory defects and glycolytic impairments conferred by INPP1 knockdown. (A,B) The migratory impairment in
shINPP1 SKOV3 ovarian (A) and C8161 melanoma (B) cells is fully rescued upon treating cells with low concentrations of LPA (100 nM).
Treatment with DMSO or LPA (100 nM) was initiated concurrently with the seeding of cells for assessment of cancer cell migration (24 h). (C)
Reduced [13C] incorporation into glycolytic intermediates from labeling siINPP1 cells with [13C]glucose (24 h) is rescued upon treatment of cells
with LPA (1 μM). Treatment with LPA was initiated 2 days after transfection of siINPP1 oligonucleotides and 24 h prior to labeling of cells with
either [12C] or [13C]glucose (10 mM, 24 h). (D) Isotopic incorporation into glycolytic intermediates is reduced upon treating SKOV3 cells with the
LPA antagonist Ki16425 (10 μM). The antagonist or DMSO was pretreated with SKOV3 cells 24 h prior to seeding of cells for labeling with [12C]
or [13C]glucose (10 mM, 24 h). For panels C and D, isotopic incorporation of [13C]glucose into glycolytic intermediates and glycerol-3-phosphate
were quantiﬁed by SRM-based LC−MS/MS. (E) The reduction in GLUT1 and HK2 expression conferred by INPP1 knockdown is partially to fully
rescued by LPA (1 μM). (F) Model depicting the metabolic role of INPP1 in controlling glycolytic metabolism and LPA signaling. Data are average
± SEM, n = 3−5/group. Signiﬁcance is expressed in panels A, B, and E as *p < 0.05 comparing shControl to all other groups and #p < 0.05
comparing the LPA-treated shINPP1 to DMSO-treated shINPP1 groups. Signiﬁcance in panel C is expressed as *p < 0.05 comparing siINPP1 with
siControl groups and #p < 0.05 comparing LPA-treated siINPP1 with DMSO-treated siINPP1 groups. Signiﬁcance in panel D is expressed as *p <
0.05 comparing Ki16425-treated and DMSO-treated groups.
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fructose-6-phosphate (fructose-6-P) and fructose-1,6-bisphos-
phate (fructose-1,6-BP) that are not observed in shINPP1 cells.
This may be due to better knockdown of INPP1 with the si
oligonucleotide compared with our shINPP1 lines (Supple-
mentary Table S1 and Supplementary Figure S2A,B). The
speciﬁcity of these metabolite changes were conﬁrmed by two
independent siRNA oligonucleotides targeting INPP1 as well as
partial to full rescue of metabolite changes by reinforced
expression of INPP1 in siINPP1 SKOV3 cells (Supplementary
Figure S2A,B). While we could not detect important
phosphatidylinositol species such as phosphatidylinositol bi-
sphosphate due to limitations in our metabolomic proﬁling,
other inositol polyphosphates, such as IP5 and IP6, were
unchanged (Supplementary Figure S2C). Nonetheless, measur-
ing phosphorylated phosphatidylinositol species will be of
future interest and important in fully understanding the role of
INPP1 in cancer.
While we do not yet understand how INPP1 alters
asparagine levels, our results collectively indicate that INPP1
may modulate glycolytic pathways that feed into glycerophos-
pholipid biosynthesis. Although INPP1 overexpression is not
suﬃcient to confer increased aggressiveness in SKOV3 cells, it
is suﬃcient to increase the levels of glycolytic intermediates and
LPA (Supplementary Figure S3A,B). Taken together these
results indicate that INPP1 is both necessary and suﬃcient to
control the levels of glycolytic intermediates and LPA in cancer
cells.
INPP1 Exerts Control over Glycolytic Metabolism and
Glucose-Derived LPA Synthesis in Cancer Cells. Based on
our metabolomic proﬁling data, we hypothesized that INPP1
inactivation was leading to impairments in glycolytic metabo-
lism. Consistent with this premise, we ﬁnd that INPP1 ablation
decreases both media glucose consumption and lactate
secretion in a time-dependent manner (Figure 4A). We also
show that glucose consumption is signiﬁcantly increased upon
INPP1 overexpression in SKOV3 cells (Supplementary Figure
S3C). Reinforcing this data, we also show that isotopic
incorporation of [U-13C]glucose into [13C]glycolytic inter-
mediates, glycerol-3-P, and LPA (13C incorporation in the
glycerol backbone) are also signiﬁcantly lowered upon INPP1
knockdown under steady-state labeling conditions (Figure 4B,
Supplementary Figure S4; full isotopomer analysis shown in
Supplementary Figure S5). Taken together, these results
indicate that INPP1 knockdown impairs glycolytic metabolism
and glucose-derived LPA levels.
Given that glycolytic metabolism appears to be markedly
impaired with INPP1 knockdown, we next asked whether the
enzymes that are responsible for importing, trapping, or
metabolizing glucose within the cell might be altered as well.
Indeed, we ﬁnd that INPP1 knockdown in SKOV3 cells leads
to a marked downregulation in glucose transporter 1 (GLUT1),
GLUT4, and hexokinase (HK2) expression, and we show
partial to full reversal of these changes upon reinforced
expression of INPP1 (Figure 4C, Supplementary Figure S6).
Interestingly, we ﬁnd that in C8161 cells, INPP1 knockdown
leads to a downregulation in HK1 expression, but not GLUT1/
4 or HK2 expression (Figure 4C). Taken together, our results
indicate that INPP1 ablation may lead to impairments in
glycolytic metabolism and lowering of glucose-derived LPA
levels that are the result of transcriptional alterations to both
glucose transporters and hexokinase.
On the basis of these metabolic alterations, we surmised that
the pathogenic impairments conferred by INPP1 knockdown
might also result from lowered glycolysis and LPA synthesis.
Indeed, we ﬁnd that inhibition of glycolysis by the
phosphoglucose isomerase (PGI) inhibitor 2-deoxyglucose
(2DG) recapitulates the antimigratory phenotype and lowering
of post-PGI glycolytic intermediates and LPA levels (Figure
4D). Furthermore, we show that the migratory impairments
caused by INPP1 knockdown are partially rescued by enforced
expression of GLUT4 (Figure 4E).
Regulation of Glycolytic Metabolism and Cancer Cell
Pathogenicity by LPA. Next, we wanted to understand the
mechanism through which INPP1 was modulating cancer
pathogenicity and glycolytic and lipid metabolism. While our
data suggested that we were impairing glycolytic metabolism,
we discounted energetic impairments as a cause for the
observed pathogenic impairments since ATP levels were not
consistently lower in INPP1 knockdown SKOV3 and C8161
cells (Supplementary Table S1). Interestingly, LPA has been
well-studied as a potent oncogenic signaling lipid that acts
through LPA receptor signaling to drive multiple stages of
cancer including migration, invasion, and tumorigenicity.13 We
therefore hypothesized that INPP1 may be modulating cancer
cell migration through controlling LPA synthesis and signaling.
Consistent with this premise, low concentrations of LPA (100
nM), which did not stimulate basal migration, fully rescue the
migratory defects conferred by INPP1 knockdown (Figure
5A,B), indicating that LPA may possibly be involved in the
mechanism through which INPP1 drives cancer pathogenicity.
We next wanted to determine whether this reduced LPA
signaling in INPP1 knockdown cells was also leading to
decreased glycolytic metabolism. Consistent with this premise,
we ﬁnd that LPA rescues the impaired glycolytic metabolism
that feeds into glycerol-3-P synthesis in siINPP1 SKOV3 cells
(Figure 5C). We also ﬁnd that LPA receptor antagonism (with
Ki16425, 10 μM14) reduces isotopic incorporation of [13C]-
glucose into glycolytic intermediates and glycerol-3-P (Figure
5D). The transcriptional downregulation of GLUT1 and HK2
observed with INPP1 knockdown are also partially to fully
rescued upon addition of LPA (Figure 5E). Thus, our results,
though correlative, indicate that reduced LPA levels and LPA
receptor signaling may in part be responsible for the glycolytic
impairments observed upon INPP1 knockdown, which in turn
may further lower glucose-derived LPA levels.
Since the PI3K/AKT and MAPK pathways have been shown
to act downstream of LPA to exert control over both glucose
transporters and glycolytic enzymes,1,15 we next asked whether
the AKT or MAPK signaling pathway might be perturbed upon
INPP1 inactivation under serum-free conditions. Paradoxically,
we ﬁnd that the levels of both phospho-AKT (p-AKT) and p-
ERK are increased upon INPP1 knockdown (Supplementary
Figures S7A,B). While we cannot fully explain these ﬁndings,
Zhong et al. previously showed that inhibition of glycolysis by
2-DG also paradoxically leads to signiﬁcant increases in both p-
AKT and p-ERK, as a compensatory mechanism for
maintaining cell survival.16 It may thus be possible that
INPP1 knockdown and subsequent glycolytic impairments
may upregulate AKT and MAPK signaling pathways to
maintain cellular survival.
Recently, Yu et al. and Cai et al. discovered that LPA also
acts upstream of the Hippo signaling pathway to promote the
migration of ovarian cancer cells through the inhibition of the
YAP kinase, LATS, resulting in the dephosphorylation and
nuclear localization of YAP, activating a transcriptional program
to promote cell migration.17,18 Interestingly, Cai et al. also
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showed that LPA-induced YAP activation promotes the
activation of downstream epidermal growth factor receptor
(EGFR) signaling, which has previously been shown to drive
glycolytic metabolism in cancer cells.18−20 Thus, the metabolic
and pathophysiological eﬀects observed with INPP1 inactiva-
tion may act through the Hippo transducer YAP. Indeed, we
ﬁnd that INPP1 knockdown signiﬁcantly increases YAP
phosphorylation (p-YAP), and this is partially rescued by
addition of LPA (100 nM) (Figure 6A). We show that
knockdown of YAP also impairs glucose consumption and
lactic acid secretion, suggesting that YAP may inﬂuence
glycolytic metabolism (Figure 6B).
Thus, we show that INPP1 inactivation leads to glycolytic
impairments and lowering of glucose-derived LPA levels and
that INPP1 ablation impairs cellular migration, invasiveness,
and tumor growth in ovarian and melanoma cancer cells. While
our results are still highly correlative and there are likely to be
additional mechanisms mediating INPP1 eﬀects upon cancer,
we provide compelling evidence that INPP1 inactivation may
impair cancer pathogenicity and glycolytic metabolism, through
lowering LPA and possibly attenuating LPA-Hippo signaling
pathways through heightened YAP phosphorylation.
Conclusion. In this study, we demonstrate INPP1 as a
highly expressed metabolic enzyme in aggressive ovarian and
melanoma cancer cells and primary human tumors. We show
that INPP1 is a unique metabolic node that controls glycolytic
metabolism and glucose-derived LPA synthesis. We also show
that INPP1 inactivation leads to impairments in cancer cell
pathogenicity possibly through impaired LPA signaling through
modulating the Hippo pathway.
A key critical question that remains is the mechanism of how
INPP1 lowers LPA levels and signaling and how INPP1 aﬀects
glycolytic metabolism. It is still unclear whether lower LPA
levels or impaired glycolytic metabolism occurs ﬁrst upon
INPP1 knockdown, but we provide compelling evidence that
LPA and glycolytic metabolism are intricately linked and that
INPP1 modulates this coupled metabolic and signaling
programming in cancer cells. We surmise that a decrease in
the downstream products (inositol phosphates and free
inositol) or an increase in the upstream reactants (inositol
polyphosphates) may lead to transcriptional changes within the
cell that result in glycolytic impairment and/or a decrease in
cellular LPA levels. Alternatively, there may be yet unknown
inositol phosphate pathways that feed into supplying glycolytic
intermediates or LPA that are initially lowered to instigate this
process.
We previously showed that one of the enzymes upregulated
across aggressive cancer cells, monoacylglycerol lipase
(MAGL), was the primary lipolytic enzyme that released free
fatty acids in cancer cells, which were remodeled into
oncogenic signaling lipids such as LPA, prostaglandins, and
other lysophospholipids.4 Quite interestingly, while MAGL
provides the fatty acids to be esteriﬁed onto glycerophospho-
lipids, INPP1, by controlling the cellular uptake of glucose,
provides the glycerol-3-P backbone for this reaction, both
collectively leading to the synthesis of LPA. We previously
showed that MAGL conferred aggressive features to cancer
cells also through modulating fatty acid-derived LPA and
prostaglandin signaling. It will therefore be intriguing to
determine whether blocking both INPP1 and MAGL leads to
additive or synergistic eﬀects by blocking both the generation of
fatty acids and the glycerol-3-phosphate backbone for LPA
synthesis.
In summary, we put forth INPP1 as a critical metabolic node
that uniquely regulates glycolytic metabolism and oncogenic
lipid signaling pathways to promote cancer motility, invasive-
ness, and tumorigenicity. Furthermore, we show that INPP1
mediates this eﬀect on glycolysis possibly through LPA
signaling, highlighting a unique intersection between lipid
signaling pathways and central carbon metabolism in cancer
cells. INPP1 may thus be an attractive therapeutic target for
combatting malignant human cancers.
■ METHODS
Materials. All cell lines, with the exception of C8161, MUM2C,
and 231MFP, were purchased from ATCC. The C8161 and MUM2C
lines were provided by Mary Hendrix. The 231MFP cells were
generated from explanted xenograft tumors of MDA-MB-231 cells, as
described previously.21
Cell Culture Conditions. HEK293T cells were cultured in
DMEM media containing 10% FBS and maintained at 37 °C with
5% CO2. SKOV3 and C8161 cells were cultured in RPMI1640 media
containing 10% FBS and glutamine maintained at 37 °C at 5% CO2.
PC3 cells were cultured in F12K media containing 10% FBS and
glutamine and were maintained at 37 °C at 5% CO2. 231MFP cells
were cultured in L15 media containing 10% FBS and glutamine and
were maintained at 37 °C in 0% CO2.
Figure 6. INPP1 knockdown aﬀects the Hippo transducer YAP. (A)
INPP1 knockdown increases phosphorylated YAP (p-YAP) protein
levels compared to siControl cells in SKOV3 cells grown in serum-free
media for 24 h by Western blotting. This increase in p-YAP is partially
rescued upon addition of LPA (100 nM, 24 h). (B) YAP was knocked
down by >75% in SKOV3 cells using two independent si
oligonucleotides, and YAP knockdown was conﬁrmed by qPCR.
After 48 h of transfection with siControl or siYAP oligonucleotides,
media was replaced, and media glucose and lactic acid levels were
measured after 24 h by glucose assay kit and SRM-based LC−MS/MS,
respectively. Data are represented as n = 3−5/group. Signiﬁcance
expressed as *p < 0.05 compared to siControl, #p < 0.05 comparing
siINPP1+LPA to siINPP1.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb5001907 | ACS Chem. Biol. 2014, 9, 1340−13501347
Quantitative PCR. Quantitative PCR was performed using the
manufacturer’s protocol for Fischer Maxima SYBRgreen, with 10 μM
primer concentrations. Further methods are found in Supporting
Information.
INPP1 Activity Assay. INPP1 phosphatase activity was measured
by an adaptation of the assay described previously.7 Brieﬂy, cell or
tumor lysate (20 μg protein) was incubated with the INPP1 substrate
inositol-1,4-bisphosphate (50 μM) for 60 min at RT in phosphate
buﬀered saline with 50 μM magnesium chloride (50 μL total reaction
volume). Heat denatured proteomes were used as a negative control.
The reactions were quenched by the addition of 1:1 acetonitrile/
methanol (200 μL), followed by centrifugation (1300 rpm, 5 min) and
collection of the supernatant for subsequent SRM-based LC−MS
analysis quantitating the formation of inositol-4-phosphate product
and subtracting background levels measured in heat-denatured
proteome negative controls.
Human Primary Ovarian Tumors. Patients were diagnosed and
treated for ovarian tumors at Brigham and Women’s Hospital and
Dana-Farber Cancer Center (Boston, MA, USA). All patient-derived
biologic specimens were collected and archived under protocols
approved by the Human Subjects Committee of the Brigham and
Women’s Hospital. The histopathologic diagnosis was determined by
the gynecological pathologists at Brigham and Women’s Hospital. The
tumors were classiﬁed and graded according to the International
Federation of Gynecology and Obstetrics (FIGO) system. For this
work, 8 benign and 14 high-grade malignant ovarian tumor samples
were used for the INPP1 activity and metabolite measurements. The
benign cases included benign cysts, ovarian ﬁbromas, and benign
serous cystadenomas, whereas the malignant cases were all high-grade
papillary serous carcinomas. Fresh tumor tissues were cut with scalpels
into 2−5 mm pieces, individually wrapped in aluminum foil, snap-
frozen in liquid nitrogen, and kept at −80 °C. INPP1 activity was
measured as described above.
MCF10A Cell Line Generation and Screening. Derivative
isogenic MCF10A cell lines were generated though stable infection
using viral infection of cell pools using either pLX304, pMSCV-Hygro,
or pMSCV-puro vectors. Control MCF10A cell lines were generated
by expressing empty vectors conferring puromycin or blasticidin gene
resistance as appropriate. Overexpression of genes was conﬁrmed by
Western blotting with speciﬁc antibodies.
Constructing INPP1 Knockdown Cells. We used both short-
hairpin (sh) and small-interfering (si) RNA using two independent
silencing oligonucleotides to knockdown the expression of INPP1. For
construction of stable shRNA knockdown lines, lentiviral plasmids
(pLKO.1) containing shRNA (purchased from Open Biosystems)
against human INPP1 were transfected into HEK293 cells using
Fugene (Roche). Lentivirus was collected from ﬁltered culture media
(0.45 μm ﬁlters) and delivered to the target cancer cell line with
Polybrene. These target cells were subsequently selected over 3 days
with 1 μg/mL puromycin. For transient knockdown of INPP1 with
siRNA (Dharmacon), cells were seeded in 6-cm dishes (200,000 cells)
for 24 h and then transfected with siRNA per manufacturer’s
instructions. The short-hairpin sequence used for constructing
shINPP1 was as follows: CCGGGCTTAGAAAGAAATCCAGAA-
ACTCGAGTTTCTGGATTTCTTTCTAAGCTTTTTG. The con-
trol shRNA was targeted against green ﬂuorescent protein with the
target sequence GCAAGCTGACCCTGAAGTTCAT. The pooled
small-interfering RNAs used to generate the siINPP1 lines were as
follows: CUGCAGAGACGCAUACCUA, GCAAAGUCCUCA-
AUGGUAA, GGUAGCAUCUGAAGCAUUA, CCAAUGAGUUUA-
CUAAUGA. The individual siRNAs 1−4 for INPP1 used in
Supplementary Figure S1 are the same as those listed above in order.
Overexpression Studies in Human Cancer Cell Lines. Stable
INPP1 overexpression was achieved by subcloning the INPP1 gene
into the pMSCVpuro vector (Clontech), generating retrovirus using
the AmphoPack-293 Cell Line, as described above with the RNA
interference studies. The human INPP1 was subcloned into the
pMSCVpuro (Clontech) by using XhoI and EcoRI restriction sites
using the following primers 5′-GTACGTACCTCGAAGATAT-
CCTCCGG-3′ and 5′-GTACGTACGAATTTATGCGTCTCTGC-
3′. For transient overexpression of INPP1 in SKOV3 cells, cells were
seeded in 6-cm dishes (200,000 cells) for 24 h and then transfected
with human INPP1 (in the mammalian SPORT6 expression vector).
At 48 h post transfection, cells were harvested for either RNA
extraction or metabolomics. For simultaneous transient mouse INPP1
overexpression and siINPP1 knockdown, cells were seeded in 6-cm
dishes (200,000 cells) for 24 h and then transfected simultaneously
with siINPP1 #1 as well as with a mouse INPP1 overexpression
construct.
Cell Migration, Cell Survival, Cell Proliferation, and Invasion
Studies. Migration, invasion, cell proliferation, and survival studies
were performed as described previously.4 Migration assays were
performed in Transwell chambers (Corning) with 8-μm pore-sized
membranes coated with collagen in which 50,000 cells were seeded
into the top chamber and chambers with ﬁxed with Diﬀ-Quik solutions
5 h after seeding cells per manufacturer’s instructions (Dade Behring).
Cells that had not migrated through the chamber on the top of the
chamber were removed with a cotton ball, and migrated cells were
counted at a magniﬁcation of 400×. An average of cells in 4 ﬁelds for
one migration chamber represents n = 1. Cell survival and proliferation
assays were performed using the Cell Proliferation Reagent WST-1
(Roche) as previously described.4 Cells were washed twice in PBS,
harvested by trypsinization, washed in serum-free media, and seeded
into 96-well plates (10,000 cells for proliferation, and 20,000 cells for
cell survival) in a volume of 200 μL for 0 and 24 h prior to addition of
WST-1 (20 μL) for 1 h at 37 °C in 5% CO2. Absorbance was then
measured at 450 nm using a spectrophotometer. Invasion assays were
conducted using the BD Matrigel Invasion Chambers per the
manufacturer’s protocol.
Tumor Xenograft Studies. Human cancer xenografts were
established by transplanting cancer cell lines ectopically into the
ﬂank of C.B17 SCID mice (Taconic Farms) as described previously.4
Brieﬂy, cells were washed two times with PBS, trypsinized, and
harvested in serum-containing medium. Next, the harvested cells were
washed two times with serum-free medium and resuspended at a
concentration of 2.0 × 104 cells/mL and 100 μL was injected. Growth
of the tumors was measured every 3 days with calipers.
Metabolomic Proﬁling of Cancer Cells. Metabolite measure-
ments were conducted using modiﬁed previous procedures.4,22 Cancer
cells were grown in serum-free media for 4 h to minimize the
contribution of serum-derived metabolites to the cellular proﬁles.
Cancer cells (1 × 106 cells/6-cm dish or 2 × 106 cells/6-cm dish for
nonpolar and polar metabolomics, respectively) were washed twice
with phosphate buﬀer saline (PBS), harvested by scraping, and isolated
by centrifugation at 1400g at 4 °C, and cell pellets were ﬂash frozen
and stored at −80 °C until metabolome extractions. Nonpolar lipid
metabolites were extracted in 4 mL of a 2:1:1 mixture of chloroform/
methanol/Tris buﬀer with inclusion of internal standards C12:0
dodecylglycerol (10 nmol) and pentadecanoic acid (10 nmol).
Organic and aqueous layers were separated by centrifugation at
1000g for 5 min, and the organic layer was collected. The aqueous
layer was acidiﬁed (for metabolites such as LPA) by adding 0.1%
formic acid, followed by the addition of 2 mL of chloroform. The
mixture was vortexed, and the organic layers were combined, dried
down under N2, and dissolved in 120 μL of chloroform, of which 10
μL was analyzed by both single-reaction monitoring (SRM)-based
LC−MS/MS or untargeted LC−MS. LC separation was achieved with
a Luna reverse-phase C5 column (50 mm × 4.6 mm with 5 μm
diameter particles, Phenomenex). Mobile phase A was composed of a
95:5 ratio of water/methanol, and mobile phase B consisted of 2-
propanol/methanol/water in a 60:35:5 ratio. Solvent modiﬁers 0.1%
formic acid with 5 mM ammonium formate and 0.1% ammonium
hydroxide were used to assist ion formation as well as to improve the
LC resolution in both positive and negative ionization modes,
respectively. The ﬂow rate for each run started at 0.1 mL/min for 5
min, to alleviate backpressure associated with injecting chloroform.
The gradient started at 0% B and increased linearly to 100% B over the
course of 45 min with a ﬂow rate of 0.4 mL/min, followed by an
isocratic gradient of 100% B for 17 min at 0.5 mL/min before
equilibrating for 8 min at 0% B with a ﬂow rate of 0.5 mL/min.
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Frozen cell pellets for polar metabolomic analyses were extracted in
180 μL of 40:40:20 acetonitrile/methanol/water with inclusion of
internal standard d3-serine (10 nmol). Following 30 s of thorough
vortexing and 1 min of bath sonication, the polar metabolite fraction
(supernatant) was isolated by centrifugation at 13,000g for 15 min.
Twenty microliters of this supernatant was analyzed by SRM-based
targeted or untargeted LC−MS/MS. For separation of polar
metabolites, normal-phase chromatography was performed with a
Luna-5 mm NH2 column (50 mm × 4.60 mm, Phenomenex). Mobile
phases were as follows: Buﬀer A, acetonitrile; Buﬀer B, 95:5 water/
acetonitrile with 0.1% formic acid or 0.2% ammonium hydroxide with
50 mM ammonium acetate for positive and negative ionization mode,
respectively. The ﬂow rate for each run started at 0.2 mL/min for 5
min, followed by a gradient starting at 0% B and increasing linearly to
100% B over the course of 45 min with a ﬂow rate of 0.7 mL/min,
followed by an isocratic gradient of 100% B for 17 min at 0.7 mL/min
before equilibrating for 8 min at 0% B with a ﬂow rate of 0.7 mL/min.
MS analysis was performed with an electrospray ionization (ESI)
source on an Agilent 6430 QQQ LC−MS/MS. The capillary voltage
was set to 3.0 kV, and the fragmentor voltage was set to 100 V. The
drying gas temperature was 350 °C, the drying gas ﬂow rate was 10 L/
min, and the nebulizer pressure was 35 psi. For both polar and
nonpolar targeted metabolomic analysis, representative metabolites
were quantiﬁed by SRM of the transition from precursor to product
ions at associated collision energies. These values and associated
retention times are listed in Supplementary Table 1. Untargeted LC−
MS was performed by scanning a mass range of m/z 50−1200, and
data were exported as mzdata ﬁles and uploaded to XCMSOnline
(xcmsserver.nutr.berkeley.edu) to identify metabolites that were
diﬀerentially changed. These metabolites from untargeted analysis
were putatively identiﬁed through using the METLIN online database.
Standards were purchased to conﬁrm coelution and fragmentation of
the standard with the metabolite of interest. This metabolite was then
quantiﬁed by SRM analysis. Metabolites were quantiﬁed by integrating
the area under the peak and were normalized to internal standard
values, and then levels were expressed as percent of control.
We have also extracted cells directly on the cell culture dish by
pipetting 180 μL of −20 °C 40:40:20 acetonitrile/methanol/water
directly onto the cells, followed by vortexing the resulting cellular
metabolome mixture and centrifugation at 10,000g for 10 min. The
supernatant was then analyzed by SRM-based analysis, and isotopic
levels of glycolytic intermediates from [13C]glucose labeling of cells for
24 h were compared between the on-plate extraction procedure and
extraction of isolated cell pellets kept at −80 °C. We ﬁnd that there is
no diﬀerence in the levels of isotopically incorporated glycolytic
intermediates between the on-plate extraction compared with the
extraction of isolated cell pellets (data not shown).
Analysis of Steady-State Isotopic Incorporation into
Glycolytic Metabolites. Steady-state isotopic glycolytic metabolism
was measured by labeling cells with [12C] or [13C]glucose and
quantifying both nonisotopic and isotopic incorporation into glycolytic
intermediates. Cells were treated with either 10 mM [12C]glucose or
[13C]glucose in glucose-free RPMI media, 48 h following transfection
of cells with siControl or siINPP1 oligonucleotides. Cells were
harvested 24 h after labeling with [12C]/[13C]glucose, and the polar
metabolome was extracted as previously described and analyzed by
SRM-based targeted LC−MS/MS for both nonisotopic and isotopic
glycolytic intermediates.
Western Blotting. Cells were lysed by probe sonication in PBS
containing both protease and phosphatase inhibitors. Proteins were
resolved by electrophoresis on 4−15% Tris-glycine precast Mini-
PROTEAN TGX gel (BioRad Laboratories) and transferred to PVDF
membranes using the iBlot system (Invitrogen). Blots were blocked
with 5% nonfat milk in a Tris-buﬀered saline containing Tween-20
(TBST) solution for 60 min at RT, washed in 1x TBST, and probed
with primary antibody of interest diluted in 5% BSA TBST solution.
Following 3 subsequent TBST washes, the blots were incubated in the
dark with a IR-linked secondary at RT for 1 h. Following 3 more
washes, blots were visualized using an Odyssey Li-Cor scanner.
Oncogene Overexpression in MCF10A Cells. We will fully
describe the generation of these lines in a subsequent manuscript.
Brieﬂy, the oncogenes described in Supplementary Figure 5 were
stably expressed in MCF10A cells, and infected cells were selected by
puromycin.
Glucose Consumption. Glucose consumption from RPMI media
was measured by collecting media and performing a colorimetric
glucose assay using a kit purchased from Abcam per the manufacturers
protocol.
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